Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Bertrand Lacroix.
European Urology | 2010
Jean-Christophe Bernhard; Allan J. Pantuck; Hervé Wallerand; Maxime Crepel; Jean-Marie Ferriere; L. Bellec; Sylvie Maurice-Tison; Grégoire Robert; Baptiste Albouy; G. Pasticier; Michel Soulie; D. Lopes; Bertrand Lacroix; Karim Bensalah; Christian Pfister; Rodolphe Thuret; Jacques Tostain; Alexandre de la Taille; Laurent Salomon; Clement Claude Abbou; Marc Colombel; Arie S. Belldegrun; Jean-Jacques Patard
BACKGROUND Ipsilateral recurrence after nephron-sparing surgery (NSS) is rare, and little is known about its specific determinants. OBJECTIVE To determine clinical or pathologic features associated with ipsilateral recurrence after NSS performed for renal cell carcinoma (RCC). DESIGN, SETTING, AND PARTICIPANTS We analysed 809 NSS procedures performed at eight academic institutions for sporadic RCCs retrospectively. MEASUREMENTS Age, gender, indication, tumour bilaterality, tumour size, tumour location, TNM stage, Fuhrman grade, histologic subtype, and presence of positive surgical margins (PSMs) were assessed as predictors for recurrence in univariate and multivariate analysis by using a Cox proportional hazards regression model. RESULTS AND LIMITATIONS Among 809 NSS procedures with a median follow-up of 27 (1-252) mo, 26 ipsilateral recurrences (3.2%) occurred at a median time of 27 (14.5-38.2) mo. In univariate analysis, the following variables were significantly associated with recurrence: pT3a stage (p=0.0489), imperative indication (p<0.01), tumour bilaterality (p<0.01), tumour size >4cm (p<0.01), Fuhrman grade III or IV (p=0.0185), and PSM (p<0.01). In multivariate analysis, tumour bilaterality, tumour size >4cm, and presence of PSM remained independent predictive factors for RCC ipsilateral recurrence. Hazard ratios (HR) were 6.31, 4.57, and 11.5 for tumour bilaterality, tumour size >4cm, and PSM status, respectively. The main limitations of this study included its retrospective nature and a short follow-up. CONCLUSIONS RCC ipsilateral recurrence risk after NSS is significantly associated with tumour size >4cm, tumour bilaterality (synchronous or asynchronous), and PSM. Careful follow-up should be advised in patients presenting with such characteristics.
Progres En Urologie | 2008
G. Verhoest; Maxime Crepel; Jean-Christophe Bernhard; L. Bellec; Baptiste Albouy; D. Lopes; Bertrand Lacroix; A. De La Taille; L. Salomon; C. Pfister; M. Soulié; J. Tostain; Jean-Marie Ferriere; C.C. Abbou; M. Colombel; Sébastien Vincendeau; K. Bensalah; A. Manunta; F. Guille; J.J. Patard
OBJECTIVE To evaluate the morbidity of partial nephrectomy (PN) according to tumour size and the type of indication based on a multicentre retrospective study. MATERIALS AND METHODS Seven French teaching hospitals participated in this study. Data concerning tumour size, indication for PN (elective or necessity), age, gender, TNM stage, histological type, Fuhrman grade, ASA score and performance status (ECOG) were analysed. Medical and surgical complications, intraoperative blood loss, blood transfusion rate and length of hospital stay were also studied. Statistical analysis of qualitative and quantitative variables was performed with Chi-square test (Fishers test) and Student t-test. RESULTS Six hundred and ninety one patients were included. The median tumour diameter was 3cm (0.4-18). Tumours measuring less or equal to 4cm and incidental tumours represented 77.7 and 80.7% of cases, respectively. Clear cell carcinomas represented 75.1% of malignant tumours. Some 89.1% of tumours were T1, 1.6% were N+ and 2.3% were M+. In the 486 elective indications: the operating time (p = 0.03), mean blood loss (p = 0.04), and urinary fistula rate (p = 0.01) were significantly higher in tumours greater than 4cm. These differences were not associated with an increase in the medical (p = 0.7) or surgical complication rate (p = 0.2), or the length of hospital stay (p = 0.4). CONCLUSION Broader indications for elective PN is associated with an increased morbidity but which remains acceptable. This is an important point for patient information and to guide the choice of surgical strategy, particularly in elderly, frail patients or patients with major comorbidities.
Progres En Urologie | 2008
Jean-Christophe Bernhard; Jean-Marie Ferriere; Maxime Crepel; Hervé Wallerand; L. Bellec; Bertrand Lacroix; D. Lopes; Baptiste Albouy; G. Robert; Alain Ravaud; M. Colombel; J. Tostain; C. Pfister; M. Soulié; Laurent Salomon; Alexandre de la Taille; G. Pasticier; A. Manunta; Francois Guille; Jean-Jacques Patard
OBJECTIVE To describe the practice of partial nephrectomy (PN) in France and assess its results in terms of morbidity and cancer control. MATERIAL AND METHOD Seven French University Hospitals in which nephron sparing surgery represents at least 30% of the total number of nephrectomies for renal tumour, participated in this study. All centres included, as exhaustively as possible, all their PN cases. For each patient, 70 variables were harvested in order to characterize the patient population, the indications, the operative technique, the per- and postoperative course and complications, the tumor specificities, the carcinologic control and renal function follow-up. RESULTS Seven hundred and forty-one PN, of which 579 for malignant tumours were analysed. The mean tumour size was 3.4+/-2.1 cm (0.1-18) and 20.8% of the tumours were larger than 4 cm. In 30.1% of cases, the indication was imperative. Among the PN, 12.2% were performed laparoscopically. The mean operating time was 151+/-54.2 min (55-420). The medical and surgical complications rates were respectively 15.2 and 14.7%. At a mean 38 months follow-up, the local recurrence rate was 3.5% and the specific death rate was 4.5%. CONCLUSION PN is nowadays getting a more and more widely used technique in France. This expansion is completely justified by its results and urologists must consider nephron sparing surgery as the gold standard treatment for renal tumours measuring less than 4 cm.
Progres En Urologie | 2008
G. Verhoest; Maxime Crepel; Jean-Christophe Bernhard; L. Bellec; Baptiste Albouy; D. Lopes; Bertrand Lacroix; A. De La Taille; L. Salomon; Christian Pfister; M. Soulié; J. Tostain; Jean-Marie Ferriere; C.C. Abbou; M. Colombel; Sébastien Vincendeau; K. Bensalah; A. Manunta; F. Guille; J.J. Patard
OBJECTIVE To evaluate the morbidity of partial nephrectomy (PN) according to tumour size and the type of indication based on a multicentre retrospective study. MATERIALS AND METHODS Seven French teaching hospitals participated in this study. Data concerning tumour size, indication for PN (elective or necessity), age, gender, TNM stage, histological type, Fuhrman grade, ASA score and performance status (ECOG) were analysed. Medical and surgical complications, intraoperative blood loss, blood transfusion rate and length of hospital stay were also studied. Statistical analysis of qualitative and quantitative variables was performed with Chi-square test (Fishers test) and Student t-test. RESULTS Six hundred and ninety one patients were included. The median tumour diameter was 3cm (0.4-18). Tumours measuring less or equal to 4cm and incidental tumours represented 77.7 and 80.7% of cases, respectively. Clear cell carcinomas represented 75.1% of malignant tumours. Some 89.1% of tumours were T1, 1.6% were N+ and 2.3% were M+. In the 486 elective indications: the operating time (p = 0.03), mean blood loss (p = 0.04), and urinary fistula rate (p = 0.01) were significantly higher in tumours greater than 4cm. These differences were not associated with an increase in the medical (p = 0.7) or surgical complication rate (p = 0.2), or the length of hospital stay (p = 0.4). CONCLUSION Broader indications for elective PN is associated with an increased morbidity but which remains acceptable. This is an important point for patient information and to guide the choice of surgical strategy, particularly in elderly, frail patients or patients with major comorbidities.
European Urology Supplements | 2006
J.J. Patard; Maxime Crepel; A.J. Pantuck; J. Lam; L. Bellec; M. Soulié; Baptiste Albouy; Christian Pfister; D. Lopes; L. Salomon; A. De La Taille; C.C. Abbou; Jean-Christophe Bernhard; Jean-Marie Ferriere; Bertrand Lacroix; J. Tostain; M. Colombel; X. Martin; B. Lobel; F. Guille; Robert A. Figlin; Arie S. Belldegrun
OBJECTIVE To analyse through a large multicentre series, morbidity of nephron-sparing surgery (NSS) in relation to tumour size and surgical indication. METHODS The study included patients from eight international academic centres. Age, sex, TNM stage, tumour size, Fuhrman grade, Eastern Cooperative Oncology Group performance status (ECOG-PS), surgical margins, local and distant recurrences, and overall and cancer-specific survival rates were collected and analysed. Indication for elective or mandatory NSS, medical and surgical complication rates, mean blood loss, blood transfusion, and length of hospital stay were specifically recorded for the purpose of this study. Groups were compared for qualitative and quantitative variables by using chi(2) (Fischer exact test) and Student t tests, respectively. RESULTS A total of 1048 NSS procedures were included in this study. Mean tumour size was 3.4+/-2.1cm. In 730 elective procedures mean operative time (p=0.002), mean blood loss (p=0.01), the need for blood transfusion (p=0.001), and urinary fistula rate (p=0.01) were significantly increased for tumours >4 cm. However, these differences did not result in significantly increased medical (p=0.4), surgical complication rates (p=0.6), or length of hospital stay (p=0.9). Finally, in elective procedures for malignant tumours, positive surgical margins, local or distant recurrence rates, and cancer-specific survival were not significantly different in tumours < or =4 cm and >4 cm. CONCLUSION Excellent cancer control and outcomes can be achieved with NSS in carefully selected patients with tumours >4 cm. Expanding the size indication of elective NSS results in an increased but acceptable morbidity.
Progres En Urologie | 2007
Maxime Crepel; Jean-Christophe Bernhardp; L. Bellec; Baptiste Albouym; D. Lopes; Bertrand Lacroix; Alexandre de la Taille; Laurent Salomon; Christian Pfister; Michel Soulie; Jacques Tostain; Jean-Marie Ferriere; Claude-C Abbou; Francois Guille; Karim Bensalah; Sébastien Vincendeau; A. Manunta; Marc Colombel; Jean-Jacques Patard
The Journal of Urology | 2007
Jean-Jacques Patard; Maxime Crepel; Jean-Christophe Bernhard; John S. Lam; Michel Soulie; Baptiste Albouy; Christian Pfister; D. Lopes; Alexandre de la Taille; Laurent Salomon; C.C. Abbou; Marc Colombel; Laurent Bellee; Jean-Marie Ferriere; Francois Guille; Bertrand Lacroix; Jacques Tostain; Arie S. Belldegrun; Allan J. Pantuck
Progres En Urologie | 2006
Ronan Moalic; Philippe Pacheco; A. Pages; Stéphane Lorin; Bertrand Lacroix; Jacques Tostain
European Urology Supplements | 2008
J.J. Patard; K. Bensalah; A.J. Pantuck; Tobias Klatte; Maxime Crepel; G. Verhoest; F. Guille; A. Manunta; Sébastien Vincendeau; R. Avakian; L. Bellec; M. Soulié; P. Rischmann; Baptiste Albouy; Christian Pfister; Jean-Christophe Bernhard; Jean-Marie Ferriere; Bertrand Lacroix; J. Tostain; A. De La Taille; C.C. Abbou; L. Salomon; M. Colombel; V. Ficarra; L. Cindolo; Roberto Bertini; Pierre I. Karakiewicz; F. Montorsi; Arie S. Belldegrun
The Journal of Urology | 2007
Quoc-Dien Trinh; Pierre I. Karakiewicz; Naeem Bhojani; Vincent Fournier-Cloutier; Georg C. Hutterer; Maxime Crepel; John S. Lam; Francois Guille; Baptiste Albouy; Michel Soulie; L. Bellec; D. Lopes; Christian Pfister; Jean-Christophe Bernhard; Bertrand Lacroix; Jacques Tostain; Jean-Marie Ferriere; C.C. Abbou; Marc Colombel; Arie S. Belldegrun; Laurent Salomon; Alexandre de la Taille; Allan J. Pantuck; Jean-Jacques Patard